Purpose: To evaluate feasibility of an efficacy trial comparing peripherally inserted central catheter (PICC) dressing and securement techniques to prevent complications and failure.
The use of peripherally inserted central catheters (PICCs) in pediatric patients is increasing globally (1, 2) . However, 30% of PICCs fail before completion of treatment owing to infective, vascular, or mechanical (fracture, partial or total PICC dislodgment) issues (3) . A recent meta-analysis of international observational studies (4) demonstrated high rates of failure (12.4 per 1,000 catheter-days), catheterassociated bloodstream infection (BSI) (3.1 per 1,000 catheter-days), thrombosis (0.2 per 1,000 catheter-days), and occlusion (2.2 per 1,000 catheter-days). Insertion of replacement devices is resource intensive and significantly reduces vessel health and preservation (5) . The purpose of PICC dressing and securement is 3-fold: (i) stability to prevent gross movement of the catheter and maintain central position; (ii) reduce micromotion, which may cause vascular injury; and (iii) protect skin puncture site from microbial entry and subsequent infection. PICC dressing and securement traditionally included sutures and a polyurethane dressing (6) . A landmark randomized controlled trial in 170 adults demonstrated the superiority of a sutureless securement device (SSD) (StatLock; C.R. Bard, Inc, Covington, Georgia) over sutures to prevent catheter-associated BSI (7) . SSDs have adhesive-backed foam anchor pads with hinged clamps for PICC wings and are used in addition to polyurethane dressings. Although this research has never been replicated in pediatric patients, SSDs are commonly used to secure PICCs in pediatric patients (8) .
Two new PICC securement technologies might be superior to current strategies. First, integrated securement dressings (ISDs) combine dressing and securement in 1 product, providing a single product alternative. ISDs have a reinforced border with an absorbent barrier around the clear transparent polyurethane section to encourage movement of moisture away from the insertion site. A reinforced fabric "collar" aims to reduce movement of the external catheter extension, preserving dressing integrity. Manufacturers claim no additional securement (eg, tape) is necessary. Tissue adhesive (TA) is a medical-grade "superglue" (cyanoacrylate) commonly used as an alternative to sutures for wound closure (9) and more recently has been used to improve securement of peripheral intravenous catheters (10) and nontunneled central venous access devices (11) . Simonova et al (12) additionally demonstrated tensile strength and bacteriostatic properties of TA to avoid dislodgment and penetration by gram-positive microorganisms in vitro. Despite the promise of these new PICC securement technologies, their clinical efficacy, costeffectiveness, and acceptability by patients and staff have not been tested in the pediatric population.
The aim of this study was to pilot test feasibility aspects, including intervention acceptability, compliance, and recruitment of novel dressing and securement products for inpatient pediatric PICCs, before a full-scale efficacy randomized controlled trial. The secondary aim was to compare the effectiveness of products to prevent PICC complications and failure owing to infection, occlusion, dislodgment, thrombosis, or fracture.
MATERIALS AND METHODS

Design
An external, pilot, parallel, 3-arm, randomized controlled trial of PICC dressing and securement for pediatric patients was undertaken. The study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12614001327673), and a protocol was published (13) . The Children's Health Service District, Queensland (HREC/13/ QRCH/181), and Griffith University (NRS/10/14/HREC) Human Research Ethics Committees provided ethics and governance approval. Informed consent was obtained from parents or legal guardians, with children providing Youth Assent when developmentally appropriate.
Study Setting
The study began in April 2014 at the Royal Children's Hospital, Brisbane, and owing to local hospital mergers, was completed at the Lady Cilento Children's Hospital, Brisbane, in September 2015. These are tertiary-level, specialist pediatric teaching hospitals in Brisbane, Australia, that provide full-spectrum health services to children from birth to 18 years of age.
Sample
The target sample size was 100 participants, allowing 30 per group, plus 10% for potential attrition, determined by standard pilot trial sample size recommendations (14) . Inclusion criteria were PICC insertion, patient age < 18 years, anticipated inpatient stay for > 24 hours, and written informed consent by legal parent or guardian. Patients were excluded if they had a current (< 48 h) BSI; had diseased, burned, scarred, or extremely diaphoretic skin; had skin tears surrounding the PICC insertion site; had known allergy to the study products; or had previously been enrolled in the study within the current hospital admission.
Participant and PICC Characteristics
As described in Table 1 and Table E1 (available online at www.jvir.org), most participant, PICC, and insertion characteristics were balanced across the intervention groups. Most participants had a medical diagnosis (n ¼ 81; 80%). Mean age was 7.5 years. There was some imbalance evident (> 10% difference between groups, not statistically significant) in skin integrity and number of insertion attempts required.
Interventions
Participants were randomly assigned to receive PICC dressing and securement (Fig 1a-c) 
Outcomes
The primary outcome was feasibility of a full efficacy trial, established by composite analysis of elements of eligibility, recruitment, attrition, protocol adherence, missing data, parent and health care staff satisfaction, and effect size estimates to allow sample size calculations (14, 15) . Parent (or caregiver) and health care staff levels of satisfaction and acceptability of the study products were assessed using a 0-to-10 numeric rating scale at PICC insertion and removal (16) . The parent (or caregiver) and staff were asked to rate their experience on removal to ensure consistency. The effect size estimates were based on the proportion of PICC failure (cessation of function before completion of therapy) and all-cause PICC complication. The published protocol by Ullman et al (13) provides additional definitions for the elements of PICC complications. Complications were (i) catheter-associated BSI (17) , (ii) local site infection (18) , (iii) venous thrombosis (19) , (iv) partial or complete dislodgment (18) , (v) occlusion, and (vi) PICC breakage (20) . Secondary outcomes are also described in full in the published protocol (13) and included (i) individual components of PICC complications (catheter-associated BSI, local site infection, venous thrombosis, dislodgment, occlusion, breakage) as defined previously, (ii) catheter-related BSI (17), (iii) securement dressing failure, (iv) PICC and first securement dressing dwell period, (v) skin safety, and (vi) direct product costs.
Study Procedures
The research nurse screened operating room lists for patients daily; obtained written informed consent; and initiated the randomization, which was web-based to ensure allocation concealment until study entry. Patients were randomly assigned in a 1:1:1 ratio with computer-generated and randomly varied block sizes of 3 and 6. The research nurse reviewed patients daily, collected data, and ensured safety of the study participants. Participants were included in the trial until 4 weeks after PICC insertion or study withdrawal, removal of the PICC, or hospital discharge.
Data were entered by research nurses into REDCap (Research Electronic Data CAPture [http://project-redcap. org/]). Demographic and clinical data were collected to assess success of randomization, describe the participant group, and display characteristics known to increase the risk of PICC complication and dressing integrity (eg, comorbidities, utility, skin insertion site and technique). The research nurses collected data on primary and secondary outcomes using the criteria defined beforehand.
PICC Procedures
Research nurses provided extensive education before the study to all clinicians involved with insertion and care of PICCs, including the study products. All PICCs (Cook [Cook, Inc, Bloomington, Indiana], Arrow [Teleflex, Morrisville, North Carolina], Bioflo [AngioDynamics, Inc, Latham, New York]) were polyurethane, power injectable, and inserted in an operating room or angiography suite. Ultrasound was used to puncture the vessel, and fluoroscopy was used to confirm PICC tip placement. PICCs were inserted by a qualified consultant pediatric anesthesiologist, a senior anesthetic registrar or fellow in an approved anesthetic training program, or pediatric vascular access nurse practitioner and managed by clinical staff in accordance with state and hospital policy (21) . The operator chose the PICC characteristics based on clinical judgment of patient needs and then applied the allocated products. Local hospital policy was 2% chlorhexidine gluconate in 70% alcohol for site decontamination on insertion and subsequent dressing change unless the patient had a proven allergy. To 
Statistical Analyses
Data were exported to Stata version 14.1 (StataCorp LLC, College Station, Texas) for management and analysis. Data cleaning of outlying figures and missing and implausible data was undertaken before analysis. Missing data were not imputed. All randomly assigned patients were analyzed on an intention-to-treat basis (22) , with PICCs the unit of measurement. Descriptive statistics (frequencies, percentages) were used to ascertain the primary outcome of feasibility for the larger trial. Comparability of groups at baseline was described across demographic, clinical, and device characteristics. Incidence rates (IR) of PICC failure and complication (per 1,000 catheter-days) were used to summarize the impact of the interventions, with differences evaluated by calculating 95% confidence intervals (CIs). Kaplan-Meier survival curves and log-rank test were used to compare PICC failure between groups and first dressing duration over time. Univariable Cox regressions were performed with baseline covariates at n > 10. Multivariable analysis was not done owing to failure n < 10. P values < 0.05 were considered statistically significant. Costs were calculated in 2016 Australian dollars.
RESULTS
Feasibility Outcomes
There were 101 patients recruited. As displayed in Figure 2 , most of the feasibility criteria were met with 74% of patients screened eligible and 91% of patients approached for consent agreeing to enroll. There were no participants lost to follow-up, and 6 patients (6%) (n ¼ 1, standard care arm; n ¼ 3, ISD arm; n ¼ 1, TA arm) did not have a PICC inserted, as the device was no longer required, or insufficient operating room space prompted alternative therapy. For these 6 patients, demographic data only were collected. One patient (< 1%) withdrew from the study owing to skin irritation (itchiness, redness) associated with the study product (ISD); treatment continued with the PICC dressed with standard care. With parental consent, the withdrawn participant was included in the analysis because of prolonged participation to the point of withdrawal. Two episodes of nonrandomized SSD were incorrectly added to patients in the ISD group during the study (not at baseline). The appropriate dressing was reapplied the next day; therefore, only 2 of 236 (< 1%) of total studied catheterdays were affected. Multiple additional reinforcement products, such as nonsterile tape (standard care, n ¼ 8; ISD, n ¼ 2; TA, n ¼ 7), were applied when the edges of primary dressings were noted to lift, and tubular elastic bandage (Tubigrip; M€ olnlycke Health Care, Gothenburg, Sweden) (standard care, n ¼ 29; ISD, n ¼ 26; TA, n ¼ 31) was applied to most patients in all study groups. No daily checks, primary outcome data, or secondary outcome data were missed during the study period.
PICC Failure and Complications
PICC failure occurred in 5% of participants (n ¼ 5) before completion of treatment ( Table 2) . PICC failure occurred in 2 patients (6%) in both the standard care and the ISD arms (IR 7.7 per 1,000 catheter-days [95% CI, 1.9-30.9] and IR 8.5 per 1,000 catheter-days [95% CI, 2.1-33.9], respectively), and 1 patient (3%) in the TA arm (IR 3.4 per 1,000 catheter-days [95% CI, 0.5-25.5]). These results are consistent with the Kaplan-Meier curve, which displays the PICC survival of the TA group consistently higher over time (log-rank test, P ¼ .799) (Fig 3) .
Overall PICC breakage and complete dislodgment were the most common forms of PICC failure. The ISD group represented the only intervention that did not have catheter failure owing to complete dislodgment. There was little difference between the groups in the at-risk period of Table 3) showed older age was associated with a reduced risk of failure (hazard ratio ¼ 0.62; 95% CI, 0.41-0.92), and when multiple attempts were required to achieve successful PICC insertion, the risk of failure increased 7-fold (7.18; 95% CI, 1.19-43.3).
Complications of PICC during the study period were equally spread, with 5 participants (16%) in each arm experiencing a complication. There were no documented episodes of catheter-associated BSI. Skin complications were highest in the TA group (10 of 32 [31%]); most of these were minor skin tears and resolved with no treatment other than angling the dressing away from the injury. ISD experienced the lowest 
Staff and Parental Feedback
As described in Table 2 , parental satisfaction with dressing and securement product was significantly higher with ISD (median, 9.7 of 10; P ¼ .006). Ease of first dressing application was equivalent across all groups; however, ease of product removal was also statistically higher in the ISD group (median, 9.2; P ¼ .002).
Dressing and Securement Outcomes
As described in Table 4 , mean time to first dressing change was longest for the TA group (5.5 d [IQR, 3.5-6.5 d]). These findings are consistent with the Kaplan-Meier curve of first securement life, reflecting prolonged time to first dressing change for TA participants compared with participants in the standard care or ISD group (P ¼ .087) (Fig 4) . 
DISCUSSION
Although PICC failure (5%) and complications (16%) in this trial remain unacceptably high, alternative dressing and securement methods have not been recently examined (7) . The trial investigated innovative securement strategies not previously tested in pediatric PICCs. This pilot trial confirmed the feasibility of a large efficacy trial, using previously determined feasibility criteria, a registered and published trial protocol (13), and rigorous methodology. As a pilot trial, the study design could not statistically test products for superiority. However, dislodgment and fracture were the main causes of catheter failure and partial dislodgment was the most common complication in all groups. Skin complications occurred in all groups; however, they were lowest in the ISD group (3 of 31 [10%]) compared with the standard care (5 of 32 [16%]) and the TA (10 of 32 [31%]) groups. Most TA complications were minor skin tears, which resolved without treatment. Although TA was removed easily from patients' skin, repeated use at each dressing replacement led to buildup on the PICC body, which was difficult to remove. Use of TA at insertion only-2 drops at the PICC insertion site-is sufficient. The average increase of 2 days until first dressing change in the TA group supports its use as an adjunct to other dressings, including ISD, and securement technologies to provide immediate hemostasis (23) , reduce postoperative bleeding, and reduce the need for early dressing change. A delayed first dressing change reduces the risk of accidental dislodgment and/or infection in often distressed and uncooperative pediatric patients (24) .
Skin complications, including itchiness, rash, and blister, were common across all groups, with 1 participant withdrawing owing to skin irritation. Altered skin integrity at pediatric PICC sites is common, potentiated by the patient's age, morbidity, and additional irritation of the PICC site during dressing changes (25, 26) . Removal of adhesives can be traumatic and anxiety provoking. Identifying patients at risk for skin complication and initiating preventive strategies are vital. All products tested appear safe and were well tolerated by patients with high levels of staff and parental satisfaction with their overall performance.
PICC failure was associated with younger age and multiple insertion attempts. A recent meta-analysis of observational studies (4) also found PICC failure to be associated with younger age, especially neonates. Multiple insertion attempts have not previously been cited as a predictor of PICC failure. Investment in research, education, and training to improve PICC insertion technique and maintenance procedures is necessary to reduce failure, especially in these high-risk populations.
Although innovative PICC securement products have a higher purchase price than traditional approaches, the potential to avoid even 1 dressing replacement can provide overall cost benefit. Additionally, if these strategies reduce PICC failure and complications, large savings in health care costs would result. The sequelae of failed PICCs include treatment delays while awaiting replacement PICCs, increased hospital length of stay, and threat to vessel health and preservation with additional unplanned access. Additional up-front investment in superior dressing and securement products to reduce the risk of complication and failure seems sensible, and a larger study is urgently needed to inform cost-effectiveness.
Although the pilot data provided valuable information, there are limitations. Not all dressing and securement products available were evaluated in this trial. The study was carried out in inpatient wards of large tertiary pediatric hospitals in Brisbane; pediatric intensive care unit and outpatient or home care settings were not included, limiting generalizability to these populations. Patients with pre-existing skin conditions were excluded from the study, also limiting the generalizability. Participants, family members, and the research staff were not blinded to the intervention; however, it is unlikely that they would cause PICC failure owing to preference for one study product over another. A blinded infectious diseases physician determined outcomes of PICCassociated bloodstream infection, and blinded radiologic personnel assessed venous thrombosis, thus ensuring validity. Study rigor was further ensured through prospective protocol registration, independent randomization, allocation concealment until study entry, and dedicated research nurses.
In conclusion, these results suggest trials of innovative PICC securement are feasible. Innovative PICC securement techniques are as safe as, and might be more effective than, standard care; are acceptable to health care staff and parents; and may reduce the need for dressing change after insertion. Further research is required to definitively identify clinical, cost-effective methods to prevent PICC failure and improve reliability. 
